Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information

J Clin Oncol. 2008 May 10;26(14):2411-2; author reply 2412-3. doi: 10.1200/JCO.2008.16.3782.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Chlorambucil / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Disease-Free Survival
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Randomized Controlled Trials as Topic
  • Research Design

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Chlorambucil
  • Alemtuzumab